Skip to main content

Malattie Polmonari

2016 January
A phase I study for intravenous autologous mesenchymal stromal cell administrationto patients with severe emphysema
Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema.
2016 January
Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonarydisease
The increasingly high rates of morbidity and mortality due to acute and chronic lung diseases have emerged as one of the major public health issues globally.
2016 January
Health relevance of the modification of low grade inflammation in ageing (inflammageing) and therole of nutrition
Ageing is characterised by an increase in the concentration of inflammatory markers in the bloodstream, a phenomenon that has been termed “inflammageing”. The inflammatory response is beneficial as an acute, transient reaction to harmful conditions, facilitating the defence, repair, turnover and adaptation of many tissues. However, chronic and low grade inflammation is likely to be detrimental for many tissues and for normal functions.
2017 May
Mesenchymal stem cells in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a major cause of respiratory failure in critically ill patients and common outcome of various lung interstitial diseases.
2017 July
Mesenchymal Stem Cells inFibrotic Disease
Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation.
2017 August
Adipose-derived stromal cell inregenerative medicine: A review.
The application of appropriate cell origin for utilizing in regenerative medicine is the major issue. Various kinds of stem cells have been used for the tissue engineering and regenerative medicine.
2017 August
Autologous Stromal Vascular Fraction inthe Intravenous Treatment of End-StageChronic Obstructive Pulmonary Disease:A Phase I Trial of Safety and Tolerability
Chronic obstructive pulmonary disease (COPD) is a consistently progressive, ultimately fatal disease for which no treat- ment exists capable of either reversing or even interrupting its course.
2018 April
Effects of different mesenchymal stromalcell sources and delivery routes inexperimental emphysema
We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route.
2018 April
Mesenchymal stromal cell infusionmodulates systemic immunologicalresponses in stable COPD patients:A phase I pilot study
COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant.
2018 April
Combined Bone Marrow‐Derived Mesenchymal Stromal Cell Therapy and One‐Way Endobronchial Valve Placementin Patients with Pulmonary Emphysema:A Phase I Clinical Trial
One‐way endobronchial valves (EBV) insertion to reduce pulmonary air trapping has been used as therapy for chronic obstructive pulmonary disease (COPD) patients.
2018 April
Transplantation of adipose-derived mesenchymalstem cells attenuates pulmonary fibrosis of silicosisvia anti-inflammatory and anti-apoptosis effects inrats
Silicosis has been topping the list of high-incidence occupational diseases in developing countries and cannot be completely cured.
2018 July
Mesenchymal Stem Cell Therapy of PulmonaryFibrosis: Improvement with Target Combination
Although the clinical application of new drugs has been shown to be effective in slowing disease progression and improving the quality of life in patients with pulmonary fibrosis, the damaged lung tissue does not recover with these drugs.
2018 July
Clinical applications of mesenchymalstem cells in chronic lung diseases.
Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair in vivo.
2018 August
Cell Therapy in Idiopathic PulmonaryFibrosis
diopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options.
2018 September
Human Mesenchymal Stem CellSecretome from Bone Marrow or Adipose-DerivedTissue Sources for Treatment ofHypoxia-Induced Pulmonary EpithelialInjury
Alveolar epithelial dysfunction induced by hypoxic stress plays a significant role in the pathological process of lung ischemia-reperfusion injury (IRI).
2018 October
Clinical Application of Mesenchymal StemCell-Derived Extracellular Vesicle-BasedTherapeutics for Inflammatory Lung Diseases
It is currently thought that extracellular vesicles (EVs), such as exosomes and microvesicles, play an important autocrine/paracrine role in intercellular communication.
2018 October
Clinical observation of umbilical cord mesenchymal stem cell treatment ofsevere idiopathic pulmonary fibrosis:A case report
Idiopathic pulmonary fibrosis (IPF) is a degenerative disease characterized by fibrosis.
2018 November
Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinicalcourse and biomarkers profile
Bronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited.
2018 November
Mesenchymal Stem Cells for theTreatment of Idiopathic PulmonaryFibrosis
Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin
2018 November
Mesenchymal stromal cells: a noveltherapy for the treatment of chronicobstructive pulmonary disease?
COPD is characterised by tissue destruction and inflammation.
2018 December
Stem Cell Delivery with Polymer HydrogelforTreatment of Intervertebral Disc Degeneration:From 3D Culture to Design of the Delivery Device for MinimallyInvasive Therapy.
Nucleus pulposus (NP) tissue damage can induce detrimental mechanical strain on the biomechanical performance of intervertebral discs (IVDs), causing subsequent disc degeneration.